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Summary.-One hundred and nineteen unselected and similarly treated patients
with Ph1-positive chronic granulocytic leukaemia (CGL) had the precise nature of
their chromosome rearrangements producing the Ph1 studied to determine whether
this had any clinical relevance. Eighteen (15°,) did not have the usual 9/22 trans-
location and these, by life-table analysis, had a significantly shorter benign phase of
their disease than the others (P<0.01). It further appeared that possession of a non-
standard Ph' was related to age, in that whereas only 24 patients were over 60 at
diagnosis, 9 (33%) had a non-9/22 translocation (P<0.01).
As the duration of the benign phase seemed to be shorter in those over 60
irrespective of Ph' type (P<0.01), the question arose whether non-standard PhI
chromosomes were simply occurring in older patients or whether they were affecting
prognosis independently. Their independent effect was suggested by the 11 patients
under 60 with a non-9/22 Ph' who still had a significantly shorter benign phase than
the 84 of similar age with a standard Ph' (P<0.01). It is concluded that the myeloid
karyotype can provide prognostic as well as diagnostic information in patients with
CGL.
CHRONIC GRANULOCYTIC LEUKAEMIA
(CGL) is associated with possession of the
Philadelphia chromosome (Phl, a charac-
teristically altered Number 22) and is
clinically typified as a biphasic disease
with a benign phase of about 3 years fol-
lowed by malignant transformation and
subsequent survival of about 3 months.
The commonest chromosome rearrange-
ment to produce Phl is a 9/22 transloca-
tion (Rowley, 1973) butsubsequentauthors
have shown that in a minority of patients
other rearrangements can produce similar
appearances in Chromosome 22 (IHayata
et al., 1973; Gahrton et al., 1974). Although
such non-standard Phls are not thought
relevant to the clinical course ofthe disease
by Sandberg (1980) we report here a
large series which appears to contradict
this belief.
PATIENTS AND METHODS
The patients were collected over 5 years,
and all referred cases of Phl-positive CGL
which were successfully banded were included
in the series. So-called Phl-negative CGL,
and those appearing as Phl-positive acute
leukaemia were excluded. Ages ranged from
14 to 76 years with a mean of46-5. There were
59 males and 60 females.
Of the 119 patients, 103 were first karyo-
typed during the clinical benign phase and
16 were not investigated until after malignant
transformation.
Marrow samples wAere studied when pos-
sible, otherwise unstimulated blood samples
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were used, and spleens were examined from
the cases with splenectomy. Marrow samples
were incubated in TC 199 for 2 h with 041 jug/
ml colcemid, swollen with 0-075M KCl and
fixed with 3:1 ethanol/glacial acetic acid.
Slides were air-dried, stained with Leishman
stain and banded (Seabright, 1971).
Cell suspensions from blood samples or
spleens w%ere incubated in 10 ml of culture
medium (3 parts foetal calf serum: 7 parts TC
199) for 64 h, and for a further 6 h with 01
jug/ml colcemid. Harvesting and slide pre-
paration w%ere the same as with marrow
samples.
All patients were treated during the benign
phase with continuous low-dose busulphan,
interrupted as considered necessary by the
attending physician. Those few patients who
could not tolerate this drug were treated
similarly with myelobromol or hydroxyurea.
Treatment during the malignant phase varied
considerably from patient to patient and
centre to centre.
The date of malignant transformation for
a given patient wNas determined in all cases by
the attending physician. This was decided on
clinical grounds, which included loss ofdisease
control and, in some cases, the appearance of
large numbers of blast cells. For the purpose
of this study, cytogenetic criteria of trans-
formation were not used. Minimum time of
follow-up was 16 months. The duration ofthe
benign phase for the various groups was
compared by the life-table and logrank
methods of Peto et al. (1977). Patients who
died in benign phase CGL have not been used
for the statistical analysis. This includes
Cases 67 and 105 with non-standard Phi
translocations.
RESULTS
Ninety-nine out of 119 cases (83%) had
a standard 9/22 Phl translocation. Details
of 18 non-standard Phl translocations
(I5%o) are given in the Table, which shows
an apparently random involvement of
chromosomes. Three of these cases (23, 47
and 69) have been included in a previous
publication (Potter et al., 1975). Two Phi
cases (20%) showing deletion of Chromo-
some 22 were also found, and included
with the non-standard Phl translocations
in this study. Mean age at diagnosis of
the non-standard Phi cases was 54 3
years, compared with 44-9 years for cases
with a 9/22 translocation.
By life-table analysis the duration of
the benign phase was significantly shorter
for the non-standard PhI patients (median
20 months) than for those with a standard
Phi (median 43 months) (P< 0.01). It also
appeared that non-standard Ph1 trans-
locations were associated with older
patients as, of 24 patients over 60 at
diagnosis, 9 (37.50/%) had a non-standard
TABLE. Philadelphia chromosomes not simply 9/22 translocations
Phi translocation
t(3;9;22)(p21 ;q34;qll)
t(C;9;22)(q34;ql 1)
t(6;9;22)(p21 ;q34;qll)
t(5;;9 ;22)(ql3 ;q34;ql 1)
t(6;9;22)(p21 ;q34;qll)
t(3;4;9;11 ;22)(p2l ;q34;ql3;qll)
t(9;13;15;22)(q34;ql4;q22;ql 1)
t(9;15;22)(q34;ql5;qll)
t(9;13;22)(q34;q22 ;ql 1)
t(9;15;22)(q34;ql5;qll)
t(6;22)(p25 ;ql 1)
t(I2;29)(q24;ql 1)
t(l2;22)(p13;qll)
t(l7;22)(q25;ql 1)
t(3;22)(p21;ql 1)
t(7;22)(p22;ql 1)
t(15;22)(pl ;q 11)
t(11 ;22)(pl5;ql 1)
Deletions
del (22) (qll)
del (22) (qll)
Duiration of benign
phase (months)
20
> 16 Alive and well
18
> 48 Alive and well
15
Died in benign phase
45
17
18
> 20 Alive and well
> 19 Alive and well
14
26
12
10
48
23
31
> 16 Alive and w ell
Died in benign phase
Case
No.
4
10
23
40
47
67
69
82
90
124
13
21
30
32
33
59
63
66
6
105
Age
(yrs)
52
73
47
42
69
68
65
57
68
63
60
57
49
19
35
35
62
52
52
61NON-STANDARD Plhl CHROMOSOMES3
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FIGURE. Life table of(duration ofbenign phase ofCGL for 3 groups ofpatients: (A) Patients < 60 yrs
with 9/22 Phl (N=84); (B) Patients > 60 yrs with 9/22 Phl (N= 15); (C) Patients < 60 yrs with
non-standard Phl (N =l1). B and C are both significantly different from A (P<0-01, logrank).
% Untransformed CGLs refers to the proportion of patients continuing in the clinical benign phase
of their disease. Open circles represent patients still in that benign phase.
Phl compared to only 11 (11-6%) of
those <60 (P<001, x2). As those aged
60 and over at diagnosis had a significantly
shorter benign phase than the rest, irres-
pective of chromosome status (median
again 20 months vs 43 months, P < 0-01),
the question arose whether a non-standard
Phl simply occurred more frequently in
older patients who had a worse prognosis
or whether it had any independent prog-
nostic value.
An attempt to answer this was made by
comparing the duration of the benign
phase in 4 subgroups of patients; (A)
84 under 60 at diagnosis with a typical
Ph1, (B) 15 x 60+atdiagnosiswith atypical
Ph', (C) 11 under 60 at diagnosis with a
non-standard Phl, and (D) 7 x 60+ at
diagnosis with a non-standard Phl. From
this it was seen that patients in Groups
B, C and D all had a significantly shorter
benignphase thanpatients in Group A, but
did not appear to differ from each other.
The difference between Group A and
Groups B and C is shown graphically in
the figure. Group D had a median duration
of benign phase of 19 months, and did not
appear different in any way from Group
B; in other words all those 60 and over
had a poor prognosis irrespective of the
Phl translocation. The presence of non-
standard Ph' under 60, however, appeared
to be associated with a more rapidly
evolving disease a prognostic effect pre-
sumably masked by age.
DISCUSSION
The nature and significance of unusual
Phl translocations have recently been the
subject of a multicentre review (Sandberg,
1980) which concluded that the survival
of patients with such translocations did
not differ significantly from that of
patients with the standard 9/22 transloca-
tion. Our data seem to contradict this
for, although we used the duration of the
benign phase rather than survival as our
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prognostic yardstick, the clear impression
is given that non-standard Phl chromo-
somes tend to be associatedl with a worse
prognosis. They also seem associated with
older patients who, in this series, had a
worse prognosis irrespective of karyotype,
so age may have a stronger influence on
outlook.
Our methods might seem open to criti-
cism, in that it could be argued that the
duration of the benign phase is hard to
measure and depends on the bias of the
managing physician deciding when trans-
formation has occurred. This we acknow-
ledge, but would emphasize that such
bias would affect all groups of patients
equally (and thus be self-cancelling) and
that while it is hard to define in words, the
event of transformation is frequently
obvious in clinical practice. The benign
phase duration seems totally unaffected
by variations in current conservative treat-
ment.
Itis possible that, within the cytogenetic
heterogeneity of the non-standard Ph1s
we have described, there exists a better
defined subgroup which is perhaps respon-
sible for the observed effect on prognosis
of the group as a whole. Numbers are too
small to be other than suggestive, but it
may be that the complex translocations
arise more frequently in older patients
than do simple translocations involving a
chromosome other than a 9. Our data
would support this, but much greater
numbers will be needed to answer the
question with confidence. Meanwhile, any
patient with a non-standard Phl should
be regarded as potentially having a worse
outlook than those with an uncomplicated
9/22 translocation.
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